The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.10
Bid: 43.10
Ask: 46.90
Change: 1.30 (2.97%)
Spread: 3.80 (8.817%)
Open: 43.10
High: 43.10
Low: 43.10
Prev. Close: 43.70
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BMK08+CleanTreat Update

16 Apr 2021 11:00

RNS Number : 7421V
Benchmark Holdings PLC
16 April 2021
 

16 April 2021

 

Benchmark Holdings

("Benchmark" or the "Company")

 

BMK08+CleanTreatÒ Update

 

Ratification of Maximum Residue Limit under European Law

Significant milestone towards the commercialisation of BMK08 and CleanTreatÒ

 

Further to the notification made on 10 September 2020, Benchmark Holdings is pleased to announce that the MRL (Maximum Residue Limit) for its novel sea lice treatment BMK08 has now been ratified under European Law. The MRL confirms the safety of Benchmark's sea lice solution for consumers and represents a significant milestone in the regulatory approval process towards the anticipated commercial launch of BMK08 and CleanTreatÒ in Norway. The commercial launch remains subject to the grant of a Marketing Authorisation in Norway.

 

BMK08 and CleanTreatÒ is a transformational solution addressing the biggest biological challenge in salmon farming. The MRL EU ratification is the culmination of almost a decade of research and development, a rigorous trial programme and substantial capital investment by Benchmark.

 

Trond Williksen, CEO, commented:

 

"The ratification of the MRL is a further stepping stone towards commercialisation following the announcement of our first customer agreements for CleanTreatâ announced in March.

 

Sea lice continues to be the biggest biological challenge for salmon producers and Benchmark's novel solution addresses this challenge in a sustainable way both in terms of animal welfare and environmental impact."

 

Enquiries:

 

 

Benchmark Holdings plc

Tel: 020 3696 0630

Ivonne Cantu, Investor Relations Director

 

Rachel Aninakwah, Communications

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

 

 

 

MHP

 

Katie Hunt /Alistair de Kare-Silver

Tel: 020 3128 8742

benchmark@mhpc.com

 

 

 

 

 

About Benchmark 

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDKABNCBKKAQD
Date   Source Headline
30th Jun 20237:00 amRNSAppointment of Non-Executive Director
30th Jun 20237:00 amRNSTotal Voting Rights
31st May 20237:00 amRNSTotal Voting Rights
30th May 20233:30 pmRNSPCA Shareholding
30th May 202311:55 amRNSHolding(s) in Company
23rd May 20237:00 amRNSSecond Quarter and Interim results
5th May 20237:00 amRNSNotice of Q2 and Interim Results
28th Apr 20237:00 amRNSTotal Voting Rights
21st Apr 20231:00 pmRNSDirector Share Options
17th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSListing of Green NOK Bond
31st Mar 20237:00 amRNSTotal Voting Rights
21st Mar 20235:33 pmRNSShare Premium Reduction
21st Mar 20237:00 amRNSBlock Listing Six Monthly Return
17th Mar 20236:09 pmRNSHolding(s) in Company
2nd Mar 202311:12 amRNSDirector Dealings
28th Feb 20239:00 amRNSTotal Voting Rights
28th Feb 20237:00 amRNSQ1 Results
17th Feb 20237:00 amRNSAcquisition of remaining minority interest
16th Feb 20236:03 pmRNSResult of AGM
14th Feb 202311:45 amRNSNotice of Q1 Results
31st Jan 20237:00 amRNSTotal Voting Rights
27th Jan 20234:40 pmRNSSecond Price Monitoring Extn
27th Jan 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
11th Jan 20238:00 amRNSPosting of Notice of AGM
30th Dec 20227:00 amRNSTotal Voting Rights
16th Dec 20229:58 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSFirst Day of Trading on Euronext Growth Oslo
14th Dec 20229:15 amRNSCompletion of private placement & retail offering
13th Dec 20224:30 pmRNSSufficient number of shares in VPS
6th Dec 20226:21 pmRNSSuccessful private placement and retail offering
6th Dec 20227:00 amRNSLast day of bookbuilding and application period
1st Dec 20223:36 pmRNSPublication of Annual Report and Notice of AGM
1st Dec 202210:58 amRNSStatus of bookbuilding
1st Dec 20227:00 amRNSProspectus & Commencement of Bookbuilding Period
30th Nov 202210:00 amRNSTotal Voting Rights
30th Nov 20227:01 amRNSPrivate Placing & Retail Offering
30th Nov 20227:00 amRNSQ4 Results
30th Nov 20227:00 amRNSFull Year Results
25th Nov 20227:00 amRNSNotice of Results
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20224:35 pmRNSChange of Registered Office
31st Oct 20227:00 amRNSTotal Voting Rights
24th Oct 20227:00 amRNSTrading Update
19th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.